New hope for hard-to-treat lung cancer: targeted drug shows promise
NCT ID NCT05246514
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called trastuzumab deruxtecan (T-DXd) in 72 people with a specific type of advanced lung cancer (HER2-mutant non-small cell lung cancer) that has worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors and how safe it is. Participants receive the drug intravenously and are monitored for response and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-MUTANT METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Baoding, 071000, China
-
Research Site
Beijing, 100142, China
-
Research Site
Beijing, 100191, China
-
Research Site
Changchun, 130000, China
-
Research Site
Changsha, 410008, China
-
Research Site
Changsha, 410013, China
-
Research Site
Chengdu, 610041, China
-
Research Site
Chongqing, 400030, China
-
Research Site
Guangzhou, 510080, China
-
Research Site
Guangzhou, 510515, China
-
Research Site
Hangzhou, 310020, China
-
Research Site
Hangzhou, 310022, China
-
Research Site
Harbin, 150081, China
-
Research Site
Hefei, 133500, China
-
Research Site
Hefei, 230601, China
-
Research Site
Linyi, 276000, China
-
Research Site
Nanjing, 210029, China
-
Research Site
Shandong, China
-
Research Site
Shanghai, 200025, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Shenyang, 110042, China
-
Research Site
Shenzhen, 518020, China
-
Research Site
Wuhan, 430022, China
-
Research Site
Wuhan, 430060, China
-
Research Site
Xi'an, 710061, China
-
Research Site
Xiamen, 361003, China
-
Research Site
Yangzhou, 225001, China
-
Research Site
Zhengzhou, 450000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.